Table 1 Patient characteristics
Characteristics, number (%) | n = 75 (100) |
|---|---|
Age, years | |
Median | 51.0 |
Range | 28–72 |
FIGO stage | |
I | 18 (24.0) |
II | 5 (6.7) |
III | 36 (48.0) |
IV | 16 (21.3) |
Histological type | |
Serous | 50 (66.7) |
Endometroid | 9 (12.0) |
Mucinous | 8 (10.7) |
Clear cell | 6 (8.0) |
Mixed | 2 (2.6) |
Preoperative serum CA125 | |
< 500 U/mL | 42 (56.0) |
≥ 500 U/mL | 33 (44.0) |
Preoperative serum HE4 | |
Normala | 17 (22.7) |
Increased | 52 (69.3) |
Unknown | 6 (8.0) |
Multidisciplinary surgeries | |
No | 33 (44.0) |
Yes | 42 (56.0) |
Ascites | |
None | 18 (24.0) |
< 1000 ml | 36 (48.0) |
≥ 1000 ml | 21 (28.0) |
Lymph-node metastasis | |
Negative | 37 (49.3) |
Positive | 38 (50.7) |
Residual lesion | |
Optimal (R0) | 60 (80.0) |
Suboptimal (R1 + R2) | 15 (20.0) |
Ki-67 index, number (%) | |
Negative | 34 (45.3) |
Positive | 41 (54.7) |
Response to frontline therapy | |
Complete response | 69 (92.0) |
Partial response | 3 (4.0) |
Progression disease | 3 (4.0) |
PARPi maintenance | |
No | 45 (60.0) |
Yes | 30 (40.0) |
Platinum status | |
Sensitive | 62 (82.9) |
Resistant | 13 (17.1) |